TYRA - NASDAQ

Tyra Biosciences, Inc.

TYRA·NASDAQ

$26.60

-7.3%

HealthcareBiotechnology

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.58B

EPS-2.0100

P/E Ratio-13.23

Earnings Date08/06/2026

tyra

Net Interest Income

Last Annual Value

0.00

3-Year CAGR

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Tyra Biosciences, Inc. Competitors Analysis of Net Interest Income

TYRA · NASDAQ

Company	Net Interest Income	CAGR 3Y	CAGR 5Y	CAGR 10Y
Tyra Biosciences, Inc. NASDAQ:TYRA	0.00	N/A	N/A	N/A
Savara Inc. NASDAQ:SVRA	4.16M	-2.1%	N/A	N/A
ProKidney Corp. NASDAQ:PROK	13.81M	-14.5%	485.9%	N/A
Kura Oncology, Inc. NASDAQ:KURA	25.26M	24.2%	99.9%	N/A
Prime Medicine, Inc. NASDAQ:PRME	4.15M	N/A	N/A	N/A
Rezolute, Inc. NASDAQ:RZLT	5.48M	9.2%	N/A	N/A
Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI	-3.05M	N/A	N/A	N/A
EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT	11.75M	27.3%	N/A	62.6%
Geron Corporation NASDAQ:GERN	-14.54M	N/A	N/A	N/A
Day One Biopharmaceuticals, Inc. NASDAQ:DAWN	18.47M	2.4%	440.6%	N/A

Tyra Biosciences, Inc. Fair Value Envelope

TYRA · NASDAQ

Our analysis suggests that TYRA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $26.6, this represents a potential HIDDEN relative to our calculated worth for Tyra Biosciences, Inc..

HIDDEN

Intrinsic Value

Current Price: $26.6

Related Guides

Blog Categories

Continue your TYRA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.